Evercore ISI Raises Twist Bioscience (TWST) Price Target to $102 Amid AI-Driven Momentum and Risk-On Dynamics

Evercore ISI has increased its price target for Twist Bioscience (NASDAQ:TWST) to $102, while unexpectedly downgrading the stock to 'In Line' from 'Outperform,' signaling caution amid risk-on investor sentiment. In a July 6 analysis, the firm highlighted TWST's year-to-date surge of over 200%, with 85% of gains occurring post its May 21 analyst day, driven by optimism around AI-powered order momentum. Evercore ISI noted profit-taking behavior, urging investors to reassess risk-focused positions. Earlier in June, Guggenheim and Barclays also raised TWST's price targets to $107 and $95 respectively, citing growing demand in life science tools. Despite this, the report emphasizes AI-focused equities with higher upside potential and redirects attention to a 'deeply undervalued' AI stock aligned with Trump-era tariffs and reshoring trends. While TWST's synthetic DNA product line remains in high demand, the sustainability of its rally faces scrutiny.

Bora Yalın's Note: Analyst actions like these underscore how AI-integrated biotech stocks reflect both speculative enthusiasm and fundamental scrutiny. TWST's price target hike signals investor confidence in AI-driven tools amid reshoring trends, yet Evercore ISI's downgrade to 'In Line' suggests that sustained outperformance hinges on operational execution. The interplay between AI momentum and life sciences underscores a critical juncture for capital allocation in niche biotech segments.